Dry Retina Is Not Enough: Re-centering Visual Acuity in Anti-VEGF Therapy for Neovascular AMD

Anti-vascular endothelial growth factor therapy transformed neovascular age-related macular degeneration, but durability and anatomic drying gradually became proxies for efficacy. Visual acuity gains have plateaued across successive agents. Feedback-driven treatment strategies obscure differences. Future progress should be judged by meaningful improvements in visual function, not extended dosing intervals alone.